Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Athira Pharma, Inc. Director's Dealing 2022

Jun 30, 2022

35038_dirs_2022-06-30_66e887fa-8dee-4d09-8e9c-dc6d6324c6a5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-06-28

Reporting Person: MOEBIUS HANS (Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-06-28 Common Stock P 10000 $2.88 Acquired 52955 Direct